Thiotepa

"Thiotepa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).

Descriptor ID	D013852
MeSH Number(s)	D02.705.672.875 D03.383.097.217.935.960
Concept/Terms	Thiotepa Thiotepa Thio-Tepa Thio Tepa Tris(1-aziridinyl)phosphine Sulfide Thiophosphamide Triethylenethiophosphoramide Tespamin Tespamin NSC-6396 NSC-6396 NSC 6396 NSC6396 Tespa Tespa AI3-24916 AI3-24916 AI3 24916 AI324916 Girostan Girostan

Below are MeSH descriptors whose meaning is more general than "Thiotepa".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Organophosphorus Compounds [D02.705]
Phosphoramides [D02.705.672]
Thiotepa [D02.705.672.875]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Azirines [D03.383.097]
Aziridines [D03.383.097.217]
Triethylenephosphoramide [D03.383.097.217.935]
Thiotepa [D03.383.097.217.935.960]

Below are MeSH descriptors whose meaning is related to "Thiotepa".

Below are MeSH descriptors whose meaning is more specific than "Thiotepa".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Thiotepa" by people in this website by year, and whether "Thiotepa" was a major or minor topic of these publications.

Bar chart showing 5 publications over 5 distinct years, with a maximum of 1 publications in 2008 and 2011 and 2016 and 2020 and 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2008	0	1	1
2011	0	1	1
2016	1	0	1
2020	0	1	1
2022	0	1	1

Below are the most recent publications written about "Thiotepa" by people in Profiles.

Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, Nonis A, La Ros?e P, Binder M, Fabbri A, Ilariucci F, Krampera M, Roth A, Hemmaway C, Johnson PW, Linton KM, Pukrop T, G?rl?v JS, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Zanni M, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Thurner L, Cabras G, Pennese E, Ponzoni M, Deckert M, Politi LS, Finke J, Ferranti A, Cozens K, Burger E, Ielmini N, Cavalli F, Zucca E, Illerhaus G. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. 2022 07; 36(7):1870-1878.

View in: PubMed
Bujold KE, Dandekar S, Barbour M. Successful Treatment of Relapsed Pediatric Acute Myeloid Leukemia Presenting as Central Nervous System Myeloid Sarcoma: A Single-Institution Case Series. J Pediatr Hematol Oncol. 2020 05; 42(4):319-321.

View in: PubMed
Esiashvili N, Lu X, Ulin K, Laurie F, Kessel S, Kalapurakal JA, Merchant TE, Followill DS, Sathiaseelan V, Schmitter MK, Devidas M, Chen Y, Wall DA, Brown PA, Hunger SP, Grupp SA, Pulsipher MA. Higher Reported Lung Dose Received During Total Body Irradiation for Allogeneic Hematopoietic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukemia Is Associated With Inferior Survival: A Report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2019 07 01; 104(3):513-521.

View in: PubMed
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Ros?e PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rud? R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, G?rl?v JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016 May; 3(5):e217-27.

View in: PubMed
Ferreri AJ, Licata G, Foppoli M, Corazzelli G, Zucca E, Stelitano C, Zaja F, Fava S, Paolini R, Franzin A, Politi LS, Ponzoni M, Reni M. Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. Oncologist. 2011; 16(3):336-41.

View in: PubMed
Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, Louis DN, Cairncross JG, Abrey LE. A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol. 2008 Sep; 89(2):187-93.

View in: PubMed
Spodick DH. Effective management of pericardial neoplasia. Chest. 2004 Nov; 126(5):1395-6.

View in: PubMed
Eder JP, Antman K, Elias A, Shea TC, Teicher B, Henner WD, Schryber SM, Holden S, Finberg R, Chritchlow J, et al. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. J Natl Cancer Inst. 1988 Oct 05; 80(15):1221-6.

View in: PubMed

People

Explore

Similar Concepts

Top Journals